Raymond James & Associates’s Altimmune ALT Stock Holding History

Raymond James & Associates’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$94.4K	Sell	15,368 -6,623	-30%	-$44.9K	﹤0.01%	3791
2024 Q2	$146K	Sell	21,991 -99,146	-82%	-$732K	﹤0.01%	3671
2024 Q1	$1.23M	Buy	+121,137	New	+$1.23M	﹤0.01%	2468
2022 Q4	–	Sell	-31,710	Closed	-$405K	–	3918
2022 Q3	$405K	Buy	+31,710	New	+$468K	﹤0.01%	2990
2021 Q3	–	Sell	-11,786	Closed	-$116K	–	4111
2021 Q2	$116K	Buy	+11,786	New	+$161K	﹤0.01%	3811
2018 Q3	–	Sell	-1,486	Closed	-$20K	–	3641
2018 Q2	$20K	Buy	1,486 +230	+18%	+$4.53K	﹤0.01%	3499
2018 Q1	$44K	Buy	+1,256	New	+$63K	﹤0.01%	3334

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Raymond James & Associates's ALT Position: Q3 2024 in Review

Raymond James & Associates reduced its Altimmune (ALT) stake by 30% in Q3 2024, selling an estimated $44.9K and leaving 15,368 shares worth $94.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3791.

Raymond James & Associates first reported a position in ALT in Q1 2018 and has held it in 7 quarters since. The position peaked at $1.23M in Q1 2024. 169 funds tracked by Wall St. Rank hold ALT as of Q3 2024.

Raymond James & Associates held 15,368 shares of Altimmune worth $94.4K as of Q3 2024.
Raymond James & Associates sold 6,623 Altimmune shares in Q3 2024, an estimated $44.9K.
Altimmune made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3791 holding.
Raymond James & Associates first reported a position in Altimmune in Q1 2018 and has held it in 7 quarters since.
Raymond James & Associates's Altimmune position peaked at $1.23M in Q1 2024.
169 funds tracked by Wall St. Rank held Altimmune as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.